Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn DataBusiness Wire • 11/12/24
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred StockBusiness Wire • 09/12/24
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred StockBusiness Wire • 09/10/24
Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen RivalInvestors Business Daily • 09/10/24
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye DiseaseBusiness Wire • 09/10/24
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024Business Wire • 09/09/24
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/08/24
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial ResultsBusiness Wire • 08/08/24
Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)Business Wire • 07/25/24
Strength Seen in Viridian Therapeutics (VRDN): Can Its 8.7% Jump Turn into More Strength?Zacks Investment Research • 07/17/24
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye DiseaseBusiness Wire • 06/11/24
Viridian Therapeutics Announces Participation in Upcoming June Investor ConferencesBusiness Wire • 05/31/24